Ainos (AIMD) Competitors

$1.74 +0.03 (+1.75%)

Closing price 05/14/2026 03:58 PM Eastern

Extended Trading

$1.80 +0.06 (+3.51%)

As of 04:01 AM Eastern

AIMD vs. DWTX, ATOS, DARE, INCR, and TLPH

Should you buy Ainos stock or one of its competitors? MarketBeat compares Ainos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ainos include Dogwood Therapeutics (DWTX), Atossa Genetics (ATOS), Dare Bioscience (DARE), InterCure (INCR), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry.

How does Ainos compare to Dogwood Therapeutics?

Ainos (NASDAQ:AIMD) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Ainos has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

Ainos has higher revenue and earnings than Dogwood Therapeutics. Ainos is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	105.42	-$14.77M	-$2.89	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$18.90	N/A

Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 506.06%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dogwood Therapeutics is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Ainos and Ainos both had 5 articles in the media. Dogwood Therapeutics' average media sentiment score of 0.22 beat Ainos' score of 0.12 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ainos	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.1% of Dogwood Therapeutics shares are held by institutional investors. 9.8% of Ainos shares are held by company insiders. Comparatively, 0.2% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dogwood Therapeutics has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -144.01% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-144.01%	-62.00%
Dogwood Therapeutics	N/A	-2,027.44%	-31.29%

Summary

Dogwood Therapeutics beats Ainos on 8 of the 14 factors compared between the two stocks.

How does Ainos compare to Atossa Genetics?

Ainos (NASDAQ:AIMD) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Ainos has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

In the previous week, Atossa Genetics had 8 more articles in the media than Ainos. MarketBeat recorded 13 mentions for Atossa Genetics and 5 mentions for Ainos. Atossa Genetics' average media sentiment score of 0.24 beat Ainos' score of 0.12 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ainos	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atossa Genetics has a consensus target price of $36.33, suggesting a potential upside of 605.50%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

Atossa Genetics has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Atossa Genetics' return on equity of -84.91% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-144.01%	-62.00%
Atossa Genetics	N/A	-84.91%	-72.36%

12.7% of Atossa Genetics shares are held by institutional investors. 9.8% of Ainos shares are held by company insiders. Comparatively, 9.8% of Atossa Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ainos has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	105.42	-$14.77M	-$2.89	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

Summary

Atossa Genetics beats Ainos on 10 of the 16 factors compared between the two stocks.

How does Ainos compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Dare Bioscience has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Ainos has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

In the previous week, Dare Bioscience had 2 more articles in the media than Ainos. MarketBeat recorded 7 mentions for Dare Bioscience and 5 mentions for Ainos. Dare Bioscience's average media sentiment score of 0.33 beat Ainos' score of 0.12 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ainos	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dare Bioscience currently has a consensus target price of $10.00, suggesting a potential upside of 249.65%. Given Dare Bioscience's stronger consensus rating and higher probable upside, equities research analysts clearly believe Dare Bioscience is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dare Bioscience has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Dare Bioscience's return on equity of 0.00% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-56.52%
Ainos	-11,912.10%	-144.01%	-62.00%

6.7% of Dare Bioscience shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by insiders. Comparatively, 9.8% of Ainos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dare Bioscience has higher revenue and earnings than Ainos. Dare Bioscience is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	40.43	-$13.40M	-$1.25	N/A
Ainos	$120K	105.42	-$14.77M	-$2.89	N/A

Summary

Dare Bioscience beats Ainos on 12 of the 16 factors compared between the two stocks.

How does Ainos compare to InterCure?

InterCure (NASDAQ:INCR) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

InterCure has higher revenue and earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.57	-$10.37M	$0.03	27.07
Ainos	$120K	105.42	-$14.77M	-$2.89	N/A

InterCure has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Ainos has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market.

8.3% of InterCure shares are owned by institutional investors. 0.2% of InterCure shares are owned by insiders. Comparatively, 9.8% of Ainos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Ainos had 3 more articles in the media than InterCure. MarketBeat recorded 5 mentions for Ainos and 2 mentions for InterCure. InterCure's average media sentiment score of 0.43 beat Ainos' score of 0.12 indicating that InterCure is being referred to more favorably in the media.

Company	Overall Sentiment
InterCure	Neutral
Ainos	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InterCure has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. InterCure's return on equity of 0.00% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Ainos	-11,912.10%	-144.01%	-62.00%

Summary

InterCure beats Ainos on 9 of the 13 factors compared between the two stocks.

How does Ainos compare to Talphera?

Talphera (NASDAQ:TLPH) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Talphera has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Talphera's return on equity of -99.81% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-99.81%	-55.55%
Ainos	-11,912.10%	-144.01%	-62.00%

Talphera has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Ainos has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market.

Talphera has higher earnings, but lower revenue than Ainos. Talphera is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,552.68	-$14.29M	-$0.37	N/A
Ainos	$120K	105.42	-$14.77M	-$2.89	N/A

In the previous week, Talphera had 5 more articles in the media than Ainos. MarketBeat recorded 10 mentions for Talphera and 5 mentions for Ainos. Talphera's average media sentiment score of 0.65 beat Ainos' score of 0.12 indicating that Talphera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ainos	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

37.7% of Talphera shares are held by institutional investors. 3.5% of Talphera shares are held by company insiders. Comparatively, 9.8% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Talphera presently has a consensus target price of $3.00, suggesting a potential upside of 234.26%. Given Talphera's stronger consensus rating and higher possible upside, equities research analysts plainly believe Talphera is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Talphera beats Ainos on 12 of the 16 factors compared between the two stocks.

Get Ainos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIMD vs. The Competition

Export

Metric	Ainos	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.43M	$3.06B	$6.34B	$12.37B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	-0.60	18.70	20.66	25.63
Price / Sales	105.42	271.92	545.73	76.59
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	1.35	4.42	9.94	6.97
Net Income	-$14.77M	$72.19M	$3.55B	$333.62M
7 Day Performance	2.35%	-0.43%	1.70%	1.09%
1 Month Performance	8.07%	-0.96%	0.49%	3.08%
1 Year Performance	-35.91%	45.81%	39.38%	35.68%

Ainos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIMD Ainos	1.0597 of 5 stars	$1.74 +1.8%	N/A	-34.2%	$12.43M	$120K	N/A	40	News Coverage Earnings Report Gap Up High Trading Volume
DWTX Dogwood Therapeutics	2.3142 of 5 stars	$1.64 +13.8%	$12.00 +632.2%	-59.2%	$48.10M	N/A	N/A	5	Earnings Report Short Interest Increase Gap Down
ATOS Atossa Genetics	2.7694 of 5 stars	$5.80 +3.9%	$36.33 +526.4%	-66.7%	$48.05M	N/A	N/A	8	Trending News Earnings Report Analyst Revision
DARE Dare Bioscience	2.176 of 5 stars	$3.16 -3.4%	$10.00 +216.5%	-1.0%	$47.61M	$1.03M	N/A	30	News Coverage Earnings Report Short Interest Increase
INCR InterCure	0.8255 of 5 stars	$0.88 +1.5%	N/A	-46.6%	$47.19M	$270.20M	29.20	350	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIMD) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ainos (AIMD) Competitors

AIMD vs. DWTX, ATOS, DARE, INCR, and TLPH

How does Ainos compare to Dogwood Therapeutics?

Summary

How does Ainos compare to Atossa Genetics?

Summary

How does Ainos compare to Dare Bioscience?

Summary

How does Ainos compare to InterCure?

Summary

How does Ainos compare to Talphera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIMD vs. The Competition

Ainos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ainos (AIMD) Competitors

AIMD vs. DWTX, ATOS, DARE, INCR, and TLPH

How does Ainos compare to Dogwood Therapeutics?

Which has more volatility and risk, AIMD or DWTX?

Which has better earnings and valuation, AIMD or DWTX?

Do analysts recommend AIMD or DWTX?

Does the media prefer AIMD or DWTX?

Do institutionals and insiders hold more shares of AIMD or DWTX?

Is AIMD or DWTX more profitable?

Summary

How does Ainos compare to Atossa Genetics?

Which has more volatility and risk, AIMD or ATOS?

Does the media prefer AIMD or ATOS?

Do analysts recommend AIMD or ATOS?

Is AIMD or ATOS more profitable?

Do institutionals and insiders hold more shares of AIMD or ATOS?

Which has better earnings and valuation, AIMD or ATOS?

Summary

How does Ainos compare to Dare Bioscience?

Which has more volatility and risk, DARE or AIMD?

Does the media favor DARE or AIMD?

Do analysts prefer DARE or AIMD?

Is DARE or AIMD more profitable?

Do insiders & institutionals hold more shares of DARE or AIMD?

Which has better valuation and earnings, DARE or AIMD?

Summary

How does Ainos compare to InterCure?

Which has preferable valuation & earnings, INCR or AIMD?

Which has more risk and volatility, INCR or AIMD?

Do institutionals & insiders believe in INCR or AIMD?

Does the media refer more to INCR or AIMD?

Do analysts rate INCR or AIMD?

Is INCR or AIMD more profitable?

Summary

How does Ainos compare to Talphera?

Is TLPH or AIMD more profitable?

Which has more volatility & risk, TLPH or AIMD?

Which has better valuation and earnings, TLPH or AIMD?

Does the media refer more to TLPH or AIMD?

Do insiders and institutionals believe in TLPH or AIMD?

Do analysts rate TLPH or AIMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIMD vs. The Competition

Ainos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools